Aug 2026 $50 M Private placement after listing $50 to $250 million 33
Quoin Pharmaceuticals Ltd.: Private sale, Aug 2026 × Investors in this round 33 investors had bought by the notice of Sep 10, 2026: 33 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $3,000,039
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Israel People named in the notice Denise Bridget Carter · Executive Officer, Director Michael Myers · Executive Officer, Director Sally Bridget Lawlor · Executive Officer Dennis Bridget Langer · Director James Bridget Culverwell · Director Joseph Bridget Cooper · Director Michael Bridget Sember · Director Natalie Bridget Leong · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round BTIG, LLC (CRD 000122225) · New York, New York Sold in CA, CT, DE, FL, MD, NC, NJ, NY, OR, and outside the US Lake Street Capital Markets, LLC (CRD 000164447) · Minneapolis, Minnesota Sold in CA, CT, DE, FL, MD, NC, NJ, NY, OR, and outside the US Leerink Partners LLC (CRD 000039011) · New York, New York Sold in CA, CT, DE, FL, MD, NC, NJ, NY, OR, and outside the US Remarks in the notice On fees: “Consists of fees due to placement agents equal in aggregate to 6.0% of gross offering proceeds, assuming cash exercise of all warrants issued. Lead placement agent also entitled to reimbursement for reasonable out-of-pocket expenses, not included here.”On the amounts: “The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement.”On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”Signed by Sally Lawlor, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 10, 2026. Read the notice at the SEC .
equity, options SEC Oct 2025 $105 M Private placement after listing $50 to $250 million 27
Quoin Pharmaceuticals Ltd.: Private sale, Oct 2025 × Investors in this round 27 investors had bought by the notice of Oct 23, 2025: 27 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $105 M of $105 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,227,995
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Israel People named in the notice Denise Bridget Carter · Executive Officer, Director Michael Myers · Executive Officer, Director Sally Bridget Lawlor · Executive Officer Dennis Bridget Langer · Director James Bridget Culverwell · Director Joseph Bridget Cooper · Director Michael Bridget Sember · Director Natalie Bridget Leong · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 000120708) · New York, New York Sold in CA, CT, DE, KY, MD, NJ, NV, NY, TX, and outside the US Remarks in the notice On fees: “Estimated commissions and fees paid at closing include cash fee of 7% of aggregate gross proceeds of private placement (except no cash fee paid for securities purchased by a Company director) and up to $75,000 for legal and other out-of-pocket expenses.”On the amounts: “The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement.”On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers”Signed by Dr. Michael Myers, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 23, 2025. Read the notice at the SEC .
equity, options SEC Jan 2018 $4 M Private placement after listing $2 to $10 million 3
Quoin Pharmaceuticals Ltd.: Private sale, Jan 2018 × Investors in this round 3 investors had bought by the notice of Feb 9, 2018: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $280,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Israel People named in the notice Eyal Nuriel Leibovitz · Executive Officer Shai Nuriel Yarkoni · Executive Officer, Director Abraham Nuriel Nahmias · Director David Nuriel Braun · Director Kasbian Nuriel Chirich · Director Michael Nuriel Berelowitz · Director Ruhama Nuriel Avraham · Director Ruth Nuriel Ben Yakar · Director Yuval Nuriel Berman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in IL, NJ Remarks in the notice On fees: “H.C. Wainwright, LLC is also entitled to non-accountable expense reimbursement of $25,000 and warrants to purchase 24,242 ADSs exercisable at $10.31 per ADS immediately for a period of one year from the date of filing an effective registration statement.”On the amounts: “The warrants and shares underlying the warrants were issued in connection with an offering of (i) 484,848 ADSs issued in a registered direct offering, which are not subject to this Form D, and (ii) unregistered warrants to purchase up to 266,667 ADSs.”On the use of proceeds: “Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers”Signed by Eyal Leibovitz, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 9, 2018. Read the notice at the SEC .
options SEC Sep 2017 $4 M No. 1 $2 to $10 million 18
Quoin Pharmaceuticals Ltd.: Raise no. 1, Sep 2017 × Investors in this round 18 investors had bought by the notice of Sep 19, 2017: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $84,963
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Israel People named in the notice Eyal Nuriel Leibovitz · Executive Officer Shai Nuriel Yarkoni · Executive Officer, Director Abraham Nuriel Nahmias · Director David Nuriel Grossman · Director Kasbian Nuriel Chirich · Director Michael Nuriel Berelowitz · Director Ruth Nuriel Ben Yakar · Director Yuval Nuriel Berman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CA, CT, NY, and outside the US Remarks in the notice On fees: “H.C. Wainwright, LLC is also entitled to non-accountable expense reimbursement of $15,000 and up to $30,000 for certain expenses. H.C. Wainwright is entitled to warrants to purchase an aggregate of 7,492 ADSs exercisable at $10.125 per ADS for five years.”On the amounts: “The warrants and shares underlying the warrants, the subject matter of this Form D were issued in connection with an offering of (i) 531,136 ADSs issued in a registered direct offering, which are not subject to this Form D, and (ii) unregistered warrants”On the use of proceeds: “Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers”Signed by Eyal Leibovitz, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 19, 2017. Read the notice at the SEC .
options SEC